Announcements

    Drinks

      Richter Gedeon Nyrt: Russia-Ukraine conflict has limited credit rating impact
      WEDNESDAY, 02/03/2022 - Scope Ratings GmbH
      Download PDF

      Richter Gedeon Nyrt: Russia-Ukraine conflict has limited credit rating impact

      Full-year results and the announced guidance remain in line with the BBB+/Stable issuer rating despite the potential operational impact from the Russia-Ukraine conflict.

      Gedeon Richter’s full-year results have confirmed its growing sales, driven by key blockbuster cariprazine, marketed as Vraylar, whose royalties have ensured robust recurring cash flow since 2020. EVRA and Bemfola (women’s healthcare) also significantly contributed to revenues and profits. While Gedeon Richter has a sizeable exposure to Russia (around 17% of the pharma revenues and 13% of overall revenues), the market’s profitability contribution is limited. However, a loss of profits cannot be ruled out. In any case, management predicts that revenue growth from cariprazine in 2022 can compensate for any losses incurred in Russia and Ukraine.Scope anticipates that the main negative impacts from the Russia-Ukraine war will come from:

      • Difficulties in rouble conversion and a potential depreciation of Gedeon Richter’s local currency, the Hungarian forint;
         
      • The exclusion of several Russian banks from the SWIFT international banking transfer system; and
         
      • The possible nationalisation of Gedeon Richter's plant in Russia, which could result in a one-off shock, though losses would be limited if the company can retain the product licence.

      While the company reduced its sales guidance for 2022 due to uncertainties regarding the Russian business and the potential for a slight reduction in profitability, Scope’s rating case is not impacted given Gedeon Richter's strong AA financial risk profile, driven by low leverage and high liquidity buffer. Scope also highlights that Gedeon Richter is yet to make full use of the HUF 70bn in proceeds from the bond issued in 2021 under the Hungarian Central Bank’s Bond Funding for Growth Scheme.

      This publication does not constitute a credit rating action, nor does it indicate the likelihood that Scope will conduct a credit rating action in the short term. For the official credit rating action release click here. On 26 May 2021, Scope assigned a first-time issuer rating of BBB+/Stable to Gedeon Richter. 

      Related news

      Show all
      Webinar: Economic opportunities and challenges in CEE and European bank strategies in the region

      24/4/2024 Research

      Webinar: Economic opportunities and challenges in CEE and ...

      Scope affirms Naturtex’s B+ issuer rating; Outlook revised to Negative

      24/4/2024 Rating announcement

      Scope affirms Naturtex’s B+ issuer rating; Outlook revised to ...

      Scope affirms BBB+/Stable issuer rating on Hungarian pharmaceutical company Richter Gedeon

      23/4/2024 Rating announcement

      Scope affirms BBB+/Stable issuer rating on Hungarian ...

      Scope affirms SAF-HOLLAND's BBB- rating, Revises Outlook to Positive from Stable

      19/4/2024 Rating announcement

      Scope affirms SAF-HOLLAND's BBB- rating, Revises Outlook to ...

      Scope affirms Haniel’s BBB-/Stable issuer rating

      19/4/2024 Rating announcement

      Scope affirms Haniel’s BBB-/Stable issuer rating

      Scope affirms GBC's issuer rating at BB-/Negative and withdraws all ratings

      18/4/2024 Rating announcement

      Scope affirms GBC's issuer rating at BB-/Negative and ...